Cholesterol Harnesses Immune Cells to Facilitate Breast Cancer Metastasis

The link between high cholesterol and breast cancer metastasis has been well-established; however, the underlying mechanisms of this relationship were previously unknown.
 
A study published by Nature Communications sheds light on how high cholesterol can accelerate the spread of cancer. The authors discovered that a byproduct of cholesterol metabolism—27HC—hijacks immune cells to fuel breast cancer metastasis.
 
Additionally, the authors discovered a potential treatment target that could inhibit 27HC’s actions.
 
“Breast cancer impacts roughly 1 in 8 women. We’ve developed fairly good strategies for the initial treatment of the disease, but many women will experience metastatic breast cancer, when the breast cancer has spread to other organs, and at that point we really don’t have effective therapies,” said lead researcher Erik Nelson, PhD. “We want to find what drives that process and whether we can target that with drugs.”
 
In the new study, mice models of breast cancer were fed a high cholesterol diet. The authors found that high cholesterol levels drove breast cancer growth and metastasis, but this effect was less pronounced in mice treated with statins, according to the study.
 
Next, the authors inhibited the enzyme that produces 27HC during cholesterol metabolism.
 
“By inhibiting the enzyme that makes 27HC, we found a suppressor effect on breast cancer metastasis,” said first author Amy Baek, PhD. “This suggests that a drug treatment targeting this enzyme could be an effective therapeutic.”
 
Notably, there was abnormal neutrophil and T cell activity at metastatic sites high in 27HC, according to the study.
 
“Normally, your body’s immune system has the capacity to attack cancer,” Dr Nelson said, “but we found that 27HC works on immune cells to fool them into thinking the cancer is fine. It’s hijacking the immune system to help the cancer spread.”
 
Since 27HC is thought to affect the immune system rather than breast cancer, the authors believe that their findings may be applicable to many solid tumors.
 
The investigators discovered that 27HC increased metastasis in colon cancer, lung cancer, melanoma, and pancreatic cancer, which suggests that inhibiting the cholesterol byproduct could prevent metastasis for these diseases, according to the study.
 
The authors said they are currently working to understand the pathway 27HC uses to affect the immune system and whether it uses the same pathway in humans.
 
“We hope to develop small-molecule drugs to inhibit 27HC,” Dr Nelson said. “In the meantime, there are good cholesterol-lowering drugs available on the market: statins. Cancer patients at risk for high cholesterol might want to talk to their doctors about it.”


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.
This is the first time an anti-PD-1 therapy has demonstrated a survival benefit in this patient population.
Based on positive feedback on the use of CDK4/6 inhibitors as treatment for metastatic breast cancer, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, NP, remark on strategies for improving adherence to these oral therapies.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$